Impact of primary colorectal cancer site on surgical outcomes for liver metastases: A retrospective study

Table 2 Clinical data comparison of 178 patients with liver metastases from colorectal cancer, n (%)/mean ± SD

Project	Control group (n = 90)	Relapse group (n = 88)	χ2/t value	P value
Surgical method			0.24	0.625
Open surgery	16 (17.78)	19 (21.59)
Laparoscope	74 (82.22)	69 (78.41)
Blood loss			1.98	0.070
< 1000 mL	55 (61.11)	48 (54.55)
≥ 1000 mL	35 (38.89)	40 (45.45)
Intraoperative blood transfusion			0.67	0.413
Yes	44 (48.89)	40 (45.45)
No	46 (51.11)	43 (54.55)
Carcinoembryonic antigen (μg/L)	6.34 ± 1.92	7.05 ± 2.39	2.87	0.004
Carbohydrate antigen 19-9 (kU/L)	38.75 ± 13.18	41.26 ± 15.87	1.31	0.190
D-dimer (μg/L)	178.39 ± 31.74	190.34 ± 45.38	2.40	0.017
Albumin (g/L)	30.67 ± 6.45	28.96 ± 5.92	2.01	0.045
SICAM-1 (μg/L)	192.58 ± 27.93	202.45 ± 32.35	2.47	0.014
White blood cells (× 109/L)	7.82 ± 1.56	8.85 ± 2.03	2.46	0.015
Platelets (× 109/L)	220.35 ± 54.62	248.65 ± 64.36	2.14	0.034
Fibrinogen (g/L)	3.65 ± 1.03	4.51 ± 1.26	2.93	0.004
C-reactive protein (mg/L)	32.85 ± 5.69	31.18 ± 14.48	0.65	0.516
Hemoglobin (g/L)	123.69 ± 16.33	124.28 ± 17.36	0.19	0.849
Prothrombin time (s)	12.26 ± 2.75	12.83 ± 2.82	1.81	0.277
Activated partial thromboplastin time (s)	28.27 ± 6.78	28.83 ± 7.26	0.42	0.676
Efficacy of neoadjuvant chemotherapy			5.00	0.040
Effective	74 (82.22)	50 (56.82)
Invalid/not done	16 (17.78)	33 (43.18)
Targeted therapy			2.08	0.149
Yes	37 (41.11)	45 (51.14)
No	53 (58.89)	43 (48.86)
Standardized adjuvant chemotherapy after surgery			0.41	0.523
Yes	73 (81.11)	74 (84.09)
No	17 (18.89)	14 (15.91)
Clinical risk score			8.03	0.005
Yes	59 (65.56)	41 (46.59)
No	31 (34.44)	47 (53.41)

SICAM-1: Soluble intercellular adhesion molecule.